TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03935022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice
Description: Each group will randomly receive, during three different experimental days, one of the following treatments by different allocation sequences:~1. 80g of black rice Venere (Group A)~2. 80g of black rice Artemide (Group B)~3. 80g of brown rice (Group C) The three treatments will be separated by a 7 day wash-out period. After an overnight fast, volunteers will consume the rice serving within 10-15 min, immediately after the first basal blood collection at 8:00 a.m. (baseline). Other blood withdrawals will be carried out a 0.5, 1.0, 2.0 and 3.0 h after rice administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice
Description: Each group will randomly receive, during three different experimental days, one of the following treatments by different allocation sequences:~1. 80g of black rice Venere (Group A)~2. 80g of black rice Artemide (Group B)~3. 80g of brown rice (Group C) The three treatments will be separated by a 7 day wash-out period. After an overnight fast, volunteers will consume the rice serving within 10-15 min, immediately after the first basal blood collection at 8:00 a.m. (baseline). Other blood withdrawals will be carried out a 0.5, 1.0, 2.0 and 3.0 h after rice administration.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rice
Description: Each group will randomly receive, during three different experimental days, one of the following treatments by different allocation sequences:~1. 80g of black rice Venere (Group A)~2. 80g of black rice Artemide (Group B)~3. 80g of brown rice (Group C) The three treatments will be separated by a 7 day wash-out period. After an overnight fast, volunteers will consume the rice serving within 10-15 min, immediately after the first basal blood collection at 8:00 a.m. (baseline). Other blood withdrawals will be carried out a 0.5, 1.0, 2.0 and 3.0 h after rice administration.
Study: NCT00028535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given SC
Study: NCT04143295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diiodothyropropionic acid
Description: Drug Administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diiodothyropropionic acid
Description: Drug Administration
Study: NCT01506908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral nicotine
Description: oral nicotine replacement product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active
Study: NCT01923584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743 200mg
Study: NCT01240941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: dose to be determined on the Phase 1b trial (listed under a separate NCT number)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 3.6 mg orally monthly
Study: NCT01428791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIGHTEN Heart Virtual Team intervention
Description: BRIGHTEN Heart provides an interdisciplinary team evaluation of physical and mental health and on-going support for mental health \& health behavior change for 6 - 12 months, including:~• Comprehensive health risk assessment by a licensed social worker, including physical, mental, and functional status. • Virtual team case review and recommendations by interdisciplinary team including psychologist, social worker, occupational therapist, pharmacist, chaplain, dietitian, geriatric psychiatrist, and patient's primary care physician. • Development of Patient Centered Action Plan, in which the social worker assists the patient in prioritizing recommendations. • Monthly telephone calls by the social worker to support implementation of Action Plan and Case Management. • Evidence Based Psychotherapy, as needed, delivered by supervised geriatric psychology and social work fellows.
Study: NCT03144284

Intervention type: OTHER
Intervention: Knowledge, attitude, and practice survey
Description: A knowledge, attitude, and practice questionnaire is going to be distributed to dental interns.
Study: NCT02393001

Intervention type: OTHER
Intervention: Dermatology patients
Description: Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.

Intervention type: OTHER
Intervention: Dermatology patients
Description: Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.

Intervention type: OTHER
Intervention: Dermatology patients
Description: This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.

Intervention type: OTHER
Intervention: Dermatology patients
Description: Cleanse an area of unafflicted (control) skin with an alcohol swab.
Study: NCT03966859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: oral dose, once daily for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose placebo
Description: oral dose, once daily for 7 days
Study: NCT02555293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XIFAXAN® (Rifaximin)
Study: NCT03523247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: whole food, plant based diet
Description: whole food, plant based diet featuring vegetables, fruits, legumes, whole grains, seeds, and nuts
Study: NCT01557842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Treatment
Description: Class I and III antiarrhythmic drug treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
Study: NCT00548379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: vitamin D 100,000 units once in 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: olive oil 1ml
Study: NCT04637633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,
Description: topical preservative free artificial tears Q.I. D.
Study: NCT01870479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live music

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taped music
Study: NCT02708888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk training
Description: The experimental group receives 16 hours of additional trunk training (4 days/week, 4 weeks) focusing on trunk muscle strength, coordination and selective movements executed on stable and unstable surfaces.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive exercises
Description: The control group will be receiving the same amount of repetitive cognitive exercises within arm's range to ensure no anticipatory postural adjustments of the trunk.
Study: NCT01974024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).
Study: NCT00836147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avotermin (Juvista)
Description: 20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
Study: NCT01490320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAP Handout entitled, Pulling the Plug on Violence.
Description: This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Nicely Program
Description: Multimedia program available at www.playnicely.org.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Standard care in primary care clinic.
Study: NCT03975413

Intervention type: OTHER
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Longitudinal FMT study: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Study: NCT00838942

Intervention type: BEHAVIORAL
Intervention: Questionaries
Description: MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
Study: NCT00780923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: maintains upper airway patency and minimizes the obstructive events
Study: NCT01218984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 75 mg
Description: Single administration via intramuscular (IM) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 150 mg
Description: Single administration via IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 300 mg
Description: Single administration via IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone (10 mg/mL)
Description: Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone (10 mg/mL)
Description: Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone (10 mg/mL)
Description: Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Challenge and Oral Naltrexone Tolerability Testing
Description: Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Challenge and Oral Naltrexone Tolerability Testing
Description: Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Challenge and Oral Naltrexone Tolerability Testing
Description: Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
Study: NCT00911599

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood metal ion levels
Description: Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood metal ion levels
Description: Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.
Study: NCT03311308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab Injection [Keytruda]
Description: 200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: 200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg, by mouth, twice a day for nine weeks.
Study: NCT00431158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different Mechanical Ventilation Protocols
Description: OLA Group: Open lung approach protocol and recruitment maneuvers~ARDSnet Group: ARDSnet protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different Mechanical Ventilation Protocols
Description: OLA Group: Open lung approach protocol and recruitment maneuvers~ARDSnet Group: ARDSnet protocol
Study: NCT01949116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDMTX
Description: LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: 1-mg tablet of folic acid by mouth once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: 1-mg tablet of folic acid by mouth once a day
Study: NCT04688580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XW10172
Description: Various formulations
Study: NCT03621319

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid argon plasma ablation (HAPC)
Description: -The assigned HAPC ablation will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Description: -The assigned RFA procedure will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
Study: NCT02242318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03392675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring of BF and intervention
Description: Self-Monitoring: At discharge, mothers will complete daily diaries for self-monitoring to stimulate cognitive reframing on the occurrence, duration, and characteristics of nipple and breast pain, infants' latch and sucking pattern, positioning, length of each BF session, and the MAIBB.~Self-Regulation: To support self-regulation skills, mothers will be provided with several 5-minute video modules on pain and BF pain SM with additional resources links. After discharge mother will receive text message from a nurse 2X/week for BF support. Mothers may text the nurse for emergent BF support.
Study: NCT02691832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dräger double sensor
Description: The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature.
Study: NCT03380559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection, botulinum toxin + corticoid
Description: * Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection, placebo of toxin + corticoid
Description: * Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection, botulinum toxin + placebo corticoid
Description: * Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)
Study: NCT01057979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET + CM for Exercise
Description: Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET + Exercise Contracting
Description: Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
Study: NCT03464825

Intervention type: OTHER
Group type: OTHER
Intervention: Specific and progressive balance training
Description: Specific and progressive balance training for the intervention group
Study: NCT04247438

Intervention type: OTHER
Group type: OTHER
Intervention: 12h and 36h Biofilm formation on PMMA (Palapress®) dentures and samples worn by participants and brushing cycles needed to remove it.
Description: Capturing the clinical data for biofilm formation on PMMA dentures and samples worn by participants and the number of brushing cycles required to remove this biofilm.~Development of artificial denture biofilm substitute with similar mechanical properties to real denture biofilm.
Study: NCT03255616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical stimulation
Description: mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical stimulation
Description: mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibrotactile stimulation
Description: non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibrotactile stimulation
Description: non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients
Study: NCT04243356

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse control group
Description: This group will complete surveys.
Study: NCT00844064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP 12009
Description: Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles
Study: NCT02612389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditative Movement taught via DVD
Description: Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
Study: NCT00110695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle albumin bound paclitaxel followed by FEC
Description: Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. \[or if given with trastuzumab 75 mg/m2 IV over 15 min.\]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days
Study: NCT01166555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04236921
Description: single subcutaneous dose
Study: NCT02262858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan and HCTZ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Study: NCT02631837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vNOTES hysterectomy
Description: Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSC hysterectomy
Description: Surgical removal of the uterus by transabdominal laparoscopy
Study: NCT01807117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI